Treats hyperkalemia. ANDA 202333, held by Epic Pharma LLC. Sodium Polystyrene Sulfonate.
As of Nov 16, 2026, ANDA 202333 (Sodium Polystyrene Sulfonate), held by Epic Pharma LLC, was first approved by FDA on Mar 19, 2014, with 1 approved supplement and 0 published complete response letters.
Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia. Limitation of Use: Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Polystyrene Sulfonate453.6GM/BOT · powder;oral, rectal | Sodium Polystyrene Sulfonate | Rx |
| Feb 25, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 19, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters